Gyre Therapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview

• Gyre Therapeutics Inc GYRE.OQ GYRE.O is expected to show a rise in quarterly revenue when it reports results on November 7 for the period ending December 31 2025

• The San Diego California-based company is expected to report a 35.5% increase in revenue to $37.76 million from $27.87 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Gyre Therapeutics Inc is for earnings of 4 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts had fallen by about 11.1% in the last three months. ​

• Wall Street's median 12-month price target for Gyre Therapeutics Inc is $18.00, about 59.2% above its last closing price of $7.34

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated November 7 at 16:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)